Key Highlights

● Pasithea Therapeutics is pushing its oral MEK inhibitor PAS-004 through overlapping trials in rare-tumour and cancer settings, backed by three FDA designations and a $60 million cash cushion, ahead of an October poster at ESMO and NF1 data due in the fourth quarter.

● As of March 31, 2026, Pasithea held $50.4 million in cash against total liabilities of just $1.5 million and no debt, giving it a substantial cash cushion.

● All disclosed data are from small, uncontrolled, open-label cohorts; objective response rates have not been detailed, and dose-limiting toxicity could emerge at higher tablet doses now being tested.

● Investors should watch for the October ESMO poster presentation and NF1 data due later this year.

Pasithea Therapeutics Corp. (Nasdaq: KTTA), a small-cap, clinical-stage biotechnology company based in Miami Beach, Florida, has spent 2026 accumulating regulatory and clinical milestones for its lead drug, PAS-004, a next-generation macrocyclic oral MEK inhibitor. The company disclosed interim Phase 1 safety and activity data in advanced solid tumors on June 30, amended its neurofibromatosis type 1 (NF1) trial protocol on June 16 to add higher dose cohorts, and confirmed on July 21 that it will present PAS-004 data at the European Society for Medical Oncology (ESMO) Congress in Madrid this October. Those steps follow FDA Fast Track and Rare Pediatric Disease designations and a $60 million financing closed in December 2025. With a market capitalization below $15 million as of late July, investors now await two separate readouts to judge whether the clinical signal holds up.

What happened

On June 30, 2026, Pasithea reported interim results from its ongoing Phase 1 dose-escalation study of PAS-004 in MAPK-pathway-driven advanced solid tumors (NCT06299839). The company said 34 patients had been enrolled and dosed, a heavily pretreated population with a median of three prior lines of therapy (range one to eight), including refractory pancreatic and ovarian cancers. Twelve patients carried BRAF V600E mutations, and ten had previously progressed on a BRAF inhibitor or BRAF/MEK combination. Pasithea reported no dose-limiting toxicities or treatment-related discontinuations, with all treatment-related adverse events graded 1 or 2, rash in 12% of patients overall (0% among those on study more than 300 days) and diarrhea in 6%, and no cardiac or retinal toxicity. Several previously BRAF/MEK-treated patients remained on study beyond six months, and two exceeded one year, versus a published median progression-free survival of roughly five months for BRAF/MEK rechallenge. Pharmacokinetics showed a roughly 60-hour half-life with linear, dose-proportional exposure. The company is now escalating a tablet formulation through 18mg to 52mg and running a food-effect sub-study.

Why the development matters

MEK inhibitors are an established but toxicity-limited drug class, with skin, eye, and cardiac side effects historically curbing dosing and duration in approved agents. Pasithea's central argument is that PAS-004's pharmacokinetic profile could allow longer, more consistent dosing than earlier MEK inhibitors, widening potential use in RASopathies such as NF1 and MAPK-pathway-driven cancers. The interim safety data disclosed in June, low rates of high-grade toxicity and no cardiac or retinal findings among patients dosed for extended periods, is the kind of signal that, if it holds through larger, controlled studies, would support that thesis. But all disclosed results come from small, open-label, uncontrolled cohorts without an active comparator, so durability, objective response rates, and higher-dose tolerability remain unestablished in a larger population.

Company and product background

PAS-004 is Pasithea's lead clinical asset, in Phase 1 development across two indications: MAPK-pathway-driven advanced solid tumors and NF1-associated plexiform neurofibromas, with interest in RASopathies more broadly. The NF1 program holds FDA Fast Track (granted April 1, 2026) and Rare Pediatric Disease designation (granted April 20, 2026), the latter potentially making the company eligible for a Priority Review Voucher upon approval, a voucher class reported to have recently traded between roughly $150 million and $205 million, though values fluctuate and any future sale is unconfirmed. PAS-004 also holds FDA Orphan Drug designation for amyotrophic lateral sclerosis, granted June 2, 2026, an earlier-stage exploratory indication. Kartik Krishnan, M.D., Ph.D., joined as Chief Medical Officer in May 2026. Confirmed next milestones are the ESMO poster and fourth-quarter NF1 data; no registrational trial design or timeline has been disclosed.

Financial position

As of March 31, 2026, per its 10-Q filed May 15, 2026, Pasithea held $50.4 million in cash against total liabilities of just $1.5 million and no debt, with stockholders' equity of $54.8 million. It reported a Q1 net loss of $2.9 million ($2.9 million R&D expense, $1.9 million G&A expense) and used $4.8 million in operating cash. Common shares outstanding were 24.9 million as of that date, alongside 54.8 million pre-funded warrants exercisable at $0.001 and roughly 13.1 million other warrants at $0.72–$125.00, reflecting a $60 million offering (80 million shares/pre-funded warrants at $0.75 each) that closed December 2, 2025, led by Vivo Capital, Janus Henderson Investors, and other healthcare-focused institutions, with H.C. Wainwright & Co. as placement agent. Management expects this cash to fund operations through at least the first half of 2028, though burn could accelerate as later-stage cohorts enroll. As of July 29, 2026, shares outstanding stood at approximately 33.4 million and the stock closed at $0.4486, valuing the company at roughly $15 million, well below its reported cash balance.

Bull case

If interim safety trends persist at higher doses and fourth-quarter NF1 data show measurable tumor responses, PAS-004 could differentiate itself from earlier MEK inhibitors on tolerability, supporting expansion into NF1, broader RASopathies, and MAPK-driven cancers, with Fast Track and Rare Pediatric Disease status potentially accelerating regulatory timelines and enabling a future Priority Review Voucher.

Risk case

All disclosed data are from small, uncontrolled, open-label cohorts; objective response rates have not been detailed, dose-limiting toxicity could emerge at higher tablet doses now being tested, and the sub-$15 million market capitalization against a $50 million-plus cash balance may reflect investor skepticism about clinical translation, competitive dynamics, or dilution risk from outstanding warrants.

What investors should watch next

Watch for interim NF1 plexiform neurofibroma data expected in the fourth quarter of 2026; the October 23 ESMO poster for detail beyond June's update; tolerability results from the ongoing 18mg-to-52mg tablet escalation and food-effect sub-study; and the next quarterly filing (expected around August 13, 2026) for updated burn and runway figures.

Conclusion

Pasithea has strung together regulatory designations and early clinical signals for PAS-004 without yet producing the controlled, larger-scale efficacy data that would validate its commercial potential. With cash funded into 2028 on management's guidance and two data catalysts due before year-end, the stock's near-term trajectory likely hinges on whether the NF1 and solid-tumor programs convert early tolerability advantages into demonstrable clinical benefit.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.